Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the transcript. The company continues to maintain a strong balance sheet with a long-term zero debt status. No plans for raising debt or equity were discussed during the conference call. The management emphasized steady organic growth and improving financial performance without external capital infusion.

Any current/future capex/capital investment/strategic investment?

The transcript does not explicitly mention any current or future capex, capital investment, or strategic investment details. However, strategic emphasis is on diversification away from cotton and paddy towards non-cotton and non-paddy segments, which is yielding volume growth. Expansion in the Win-Chi-Win product vertical with dedicated teams indicates investment in marketing and sales infrastructure. Introduction and large-scale seed production of new hybrids in maize and paddy reflect capital allocation towards R&D and production capacity. Appointment of a crop manager for rice suggests inve

Future growth expectations in sales/revenue/volumes?

Nath Bio-Genes plans to maintain overall revenue growth of around 20% for the next year (FY22). Cotton segment growth expected around 15%, down from 25-26% this year, as cotton prices are fixed and stable. Significant growth anticipated in non-cotton segments: vegetables, paddy, bajra, maize, mustard, wheat, and rabi crops, some growing 25%-50%. Focus on diversification away from cotton and paddy, with non-cotton and non-paddy portfolio showing strong volume growth. Expansion in Win-Chi-Win product segment showing 60%-70% growth, with geographic spread increasing. Introduction of new

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims for overall revenue growth of around 18% to 20% for FY21 despite COVID-19 disruptions. Cotton segment growth is expected to be around 15% next year, with other crops like vegetables and non-cotton segments growing at higher rates (25%-50%). Win-Chi-Win segment has shown strong growth (around 60%-70%) and is expected to continue expanding with increased focus and dedicated teams. The gross margin is maintained around 52%-54%, indicating strong profitability. Profit after tax grew by 13% to 49 crores in 9 months FY21, nearing last year’s profit with a quarter remaining. EPS and

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Nath Bio-Genes (India) Limited. However, it indicates a positive outlook with plans to maintain around 20% growth overall in the next financial year. The company is gearing up well for the upcoming kharif season with sufficient production lined up. Win-Chi-Win product supply is stable without significant container shortages despite some minor trade issues. The company is increasing territories for Win-Chi-Win sales from 100 to around 175+. Seed production for new hybrids in maize and paddy is un

Nath Bio-GenesQ3 FY21Agricultural Food & other Products

Nath Bio-Genes Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹135.71P/E: 7.6Market Cap: ₹258 CrSector: Agricultural Food & other Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 2 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Nath Bio-Genes plans to maintain overall revenue growth of around 20% for the next year (FY22).
Cotton segment growth expected around 15%, down from 25-26% this year, as cotton prices are fixed and stable.
Significant growth anticipated in non-cotton segments: vegetables, paddy, bajra, maize, mustard, wheat, and rabi crops, some growing 25%-50%.
Focus on diversification away from cotton and paddy, with non-cotton and non-paddy portfolio showing strong volume growth.
Expansion in Win-Chi-Win product segment showing 60%-70% growth, with geographic spread increasing.
Introduction of new hybrids in rice and maize markets expected to drive volume increases and revenue growth.
Export opportunities expanding, especially with BT cotton hybrid registration in Sudan upcoming.
Working capital cycle improving, supporting growth plans.
Overall outlook is positive, with management confident of meeting growth guidance.

Margin guidance

Category 3

The company aims for overall revenue growth of around 18% to 20% for FY21 despite COVID-19 disruptions.
Cotton segment growth is expected to be around 15% next year, with other crops like vegetables and non-cotton segments growing at higher rates (25%-50%).
Win-Chi-Win segment has shown strong growth (around 60%-70%) and is expected to continue expanding with increased focus and dedicated teams.
The gross margin is maintained around 52%-54%, indicating strong profitability.
Profit after tax grew by 13% to 49 crores in 9 months FY21, nearing last year’s profit with a quarter remaining.
EPS and intrinsic value of shares are gradually increasing due to rising profits and stable equity.
The company is confident about maintaining or improving margins amid growth due to product quality and higher volumes.
Working capital cycle is improving, which will support better financial health going forward.

See what Nath Bio-Genes management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or future fundraising through debt or equity in the transcript.
The company continues to maintain a strong balance sheet with a long-term zero debt status.
No plans for raising debt or equity were discussed during the conference call.
The management emphasized steady organic growth and improving financial performance without external capital infusion.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Nath Bio-Genes (India) Limited.
However, it indicates a positive outlook with plans to maintain around 20% growth overall in the next financial year.
The company is gearing up well for the upcoming kharif season with sufficient production lined up.
Win-Chi-Win product supply is stable without significant container shortages despite some minor trade issues.
The company is increasing territories for Win-Chi-Win sales from 100 to around 175+.
Seed production for new hybrids in maize and paddy is underway to support volume growth.
Export registrations, particularly in Sudan, are being fast-tracked, indicating growth opportunities.
Management expresses confidence in meeting revenue guidance and improving working capital cycles.

See what Nath Bio-Genes management said on order book — free account, 30 seconds.

Capex plans

The transcript does not explicitly mention any current or future capex, capital investment, or strategic investment details.
However, strategic emphasis is on diversification away from cotton and paddy towards non-cotton and non-paddy segments, which is yielding volume growth.
Expansion in the Win-Chi-Win product vertical with dedicated teams indicates investment in marketing and sales infrastructure.
Introduction and large-scale seed production of new hybrids in maize and paddy reflect capital allocation towards R&D and production capacity.
Appointment of a crop manager for rice suggests investment in market research and product development.
Efforts to fast-track international registrations (e.g., Sudan cotton hybrids) imply strategic investments in global market expansion.
No specific monetary figures or timelines for capex or investments are disclosed in this transcript.

Track Nath Bio-Genes — get its next earnings analysis in your feed

How does Nath Bio-Genes rank vs peers in Agricultural Food & other Products?

Pro feature

ThisNath Bio-Genes

Rev 3Mar 3

See where Nath Bio-Genes sits in Agricultural Food & other ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Nath Bio-Genes rank in Agricultural Food & other Products?

Compare Nath Bio-Genes against every Agricultural Food & other Products company (Q3 FY21) on revenue, margins and earnings-call signals.

View Agricultural Food & other Products leaderboard →

What Nath Bio-Genes's management said in earlier quarters

Others in Agricultural Food & other Products this season

Mangalam Global (Q2 FY27)
The consolidated revenue from operations for the quarter ended 30-Sep-2026 is ₹98,256.41 Lakhs, up from ₹70,579.57 Lakhs in the quarter ended 30-Sep-2025…
TBI Corn Ltd (Q2 FY26)
Revenue from Operations for H1FY26: INR 1,367.0 Mn (45.5% YoY growth from H1FY25's INR 939.8 Mn). Key investor presentation takeaways from TBI Corn Ltd's Q2 FY2
GRM Overseas Ltd (Q2 FY26)
362.4 Crores, up 14.9% YoY from Rs. Key investor presentation takeaways from GRM Overseas Ltd's Q2 FY26 investor presentation — and how it ranks against sector
Uttam Sug.Mills (Q2 FY26)
561.27 Cr, up from Rs. Key investor presentation takeaways from Uttam Sugar Mills Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.

Compare:vs Marico Ltd vs Tata Consumer Products Ltd vs Patanjali Foods Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Nath Bio-Genes Q3 FY21 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Nath Bio-Genes rank in Agricultural Food & other Products?

Continue your research

What Nath Bio-Genes's management said in earlier quarters

Others in Agricultural Food & other Products this season